{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:55:38Z","timestamp":1764402938176,"version":"3.40.5"},"reference-count":18,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2020,1,21]]},"abstract":"<jats:sec>\n<jats:title>Background \/Introduction:<\/jats:title>\n<jats:p> A high prevalence of type 2 diabetes mellitus (T2DM) was\nseen in association with hepatitis C virus infection; moreover, risk of development of T2DM is increased\nabout 11 folds in patients with risk factors for metabolic syndrome in the presence of chronic\nhepatitis C virus (HCV) infection. There is a few available data on the effect of HCV eradication by\nthe new direct-acting antiviral drugs (DAAs) on the glycemic control; hence the aim of our study is to\nevaluate the glycated haemoglobin (HbA1c) level changes in type 2 diabetic chronic HCV non cirrhotic\ntreatment-na\u00efve Egyptian patients after eradication with sofosbuvir (SOV) plus daclatasvir (DCV).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Patients and Methods:<\/jats:title>\n<jats:p> A prospective observational cross-sectional study, included 128 type 2 diabetic\nHCV patients with easy to treat criteria (non cirrhotic treatment-na\u00efve patients with the following\nliver biochemical markers; total serum bilirubin \u2264 1.2 mg\/dl, serum albumin \u2265 3.5 g\/dl, INR\u2264 1.2 and\nPlatelet count\u2265 150.000\/mm3); according to the protocol of the Egyptian National Committee for Controlling\nHCV and the guidelines of the European Association for the Study of the Liver. HbA1c was\ndone for all patients enrolled in the study before starting antiviral treatment, at the end of treatment and\n3 months (12 weeks) after the end of treatment to patients who achieved sustained virological response\n(SVR) 12 only.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title> Results:<\/jats:title>\n<jats:p>According to their antidiabetic medications, patients were classified to Group I: 70 patients taking\noral hypoglycemic drugs, Group II: 58 patients taking insulin therapy +\/- oral hypoglycemic drugs.\nRegarding the glycemic profile, a statistically significant decrease of mean HbA1c % values was found\nin the studied patients (n=128), over the period of the study with p-value &lt; 0.05. For better evaluation\nof improvement of glycemic control, we used a composite endpoint given by the reduction of HbA1c\n% (of a minimum of 0.5%). The endpoint was reached to 79% (101 patients) of all studied patients 3\nmonths after the end of treatment. 75.7% (53 patients) reached the endpoint in group I, while 82.75 %\n(48 patients) of group II reached the endpoint 3 months after the end of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study supports the idea that HCV eradication leads to a reduction in HbA1c in patients\nwith diabetes, which could delay the onset and progression of microvascular diabetes complications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399815666190531091128","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T06:01:32Z","timestamp":1559282492000},"page":"165-170","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Na\u00efve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-6315","authenticated-orcid":true,"given":"Hany Aly","family":"Hussein","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-9911","authenticated-orcid":true,"given":"Ahmed Samir","family":"Allam","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-9646","authenticated-orcid":true,"given":"Ahmed Samir Abdel","family":"Moaty","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2337\/dc05-1995","volume":"29","author":"Lecube A.","year":"2006","unstructured":"Lecube A.; Hern\u00e1ndez C.; Genesc\u00e0 J.; Sim\u00f3 R.; Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 2006,29,1140-1149","journal-title":"Diabetes Care"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4239\/wjd.v5.i5.586","volume":"5","author":"Antonelli A.","year":"2014","unstructured":"Antonelli A.; Ferrari S.M.; Giuggioli D.; Hepatitis C virus infection and and type 2 diabetes mellitus. World J Diabetes 2014,5,586-600","journal-title":"World J Diabetes"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","volume":"38","author":"Mehta S.H.","year":"2003","unstructured":"Mehta S.H.; Brancati F.L.; Strathdee S.A.; Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003,38,50-56","journal-title":"Hepatology"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/apt.14482","volume":"47","author":"El-Khayat H.","year":"2018","unstructured":"El-Khayat H.; Fouad Y.; Mohamed H.I.; El-Amin H.; Kamal E.M.; Maher M.; Risk A.; Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther 2018,47,674-679","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2337\/dc05-2509","volume":"29","author":"Lecube A.","year":"2006","unstructured":"Lecube A.; Hern\u00e1ndez C.; Genesc\u00e0 J.; Sim\u00f3 R.; Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 2006,29,1096-1101","journal-title":"Diabetes Care"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","volume":"102","author":"Kawaguchi T.","year":"2007","unstructured":"Kawaguchi T.; Ide T.; Taniguchi E.; Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007,102,570-576","journal-title":"Am J Gastroenterol"},{"journal-title":"Global hepatitis report","year":"2017","key":"ref=7","unstructured":"Global hepatitis report World Health Organization2017"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.3748\/wjg.v12.i44.7075","volume":"12","author":"Romero-G\u00f3mez M.","year":"2006","unstructured":"Romero-G\u00f3mez M.; Insulin resistance and hepatitis C. World J Gastroenterol 2006,12,7075-7080","journal-title":"World J Gastroenterol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jhep.2015.08.011","volume":"63","author":"Grancini V.","year":"2015","unstructured":"Grancini V.; Trombetta M.; Lunati M.E.; Contribution of \u03b2-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. J Hepatol 2015,63,1484-1490","journal-title":"J Hepatol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","year":"2017","unstructured":"EASL Recommendations on treatment of hepatitis C. J Hepatol 2017,66(1),153-194","journal-title":"J Hepatol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(03)00187-9","volume":"39","author":"Zeuzem S.","year":"2003","unstructured":"Zeuzem S.; Heathcote E.J.; Shiffman M.L.; Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003,39,106-111","journal-title":"J Hepatol"},{"journal-title":"Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation","year":"2011","key":"ref=12","unstructured":"Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation World Health Organization2011"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.cgh.2011.05.028","volume":"9","author":"Ng V.","year":"2011","unstructured":"Ng V.; Saab S.; Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011,9,923-930","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cmi.2015.12.030","volume":"22","author":"Pavone P.","year":"2016","unstructured":"Pavone P.; Tieghi T.; d\u2019Ettorre G.; Rapid decline of fasting glucose in HCV diabetic patients treated with direct acting antiviral agents. Clinical Microbiology and Infection 2016,22(5),462","journal-title":"Clinical Microbiology and Infection"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/jmv.24897","volume":"89","author":"Abdel Alem S.","year":"2017","unstructured":"Abdel Alem S.; Elsharkawy A.; Improvement of glycemic state among responders to sofosbuvir- based treatment regimens: Single center experience. J Med Virol fouad R., et al.2017,89,2181-2187","journal-title":"J Med Virol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1381\/096089206775565122","volume":"16","author":"Harnois F.","year":"2006","unstructured":"Harnois F.; Msika S.; Sabat\u00e9 J.M.; Prevalence and predictive factors of NASH in morbidly obese patients undergoing bariatric surgery. Obes Surg 2006,16(2),183-188","journal-title":"Obes Surg"},{"key":"ref=17","volume":"3","author":"Resmi Premji.","year":"2015","unstructured":"Resmi Premji.; Nira Roopnarinesingh.; Nazia Qazi.; Eric S . Nylen.; New-Onset Diabetes Mellitus with Exposure to Ledipasvir and Sofosbuvir. Journal of Investigative Medicine High Impact Case Reports 2015,3(4)","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"Article number: 1661","DOI":"10.1038\/s41598-017-17936-4","volume":"8","author":"Silva P.","year":"2018","unstructured":"Silva P.; Kouyoumjian, Hiam Chemaitelly, Laith J. Abu-Raddad. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Scientific Reports 2018,8,Article number: 1661","journal-title":"Scientific Reports"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:41:10Z","timestamp":1582630870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172354\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399815666190531091128","relation":{},"ISSN":["1573-3998"],"issn-type":[{"type":"print","value":"1573-3998"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}